45 citations
,
November 2018 in “Journal of dermatological treatment” JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
17 citations
,
May 2019 in “BMJ Open” JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
October 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
July 2024 in “Journal of Investigative Dermatology” Baicalin may help treat severe drug-induced skin reactions.
Patients with alopecia areata using Janus kinase inhibitors are not following lab monitoring guidelines.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
November 2022 in “Journal of Investigative Dermatology” NCSTN gene mutation causes abnormal skin cell differentiation and more inflammation, contributing to Hidradenitis Suppurativa.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
3 citations
,
November 2024 in “Pediatric Dermatology” Selumetinib causes fewer and less severe skin issues in children than binimetinib.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
September 2025 in “Chinese Journal of Chromatography” A new method accurately detects illegal JAK inhibitors in hair loss cosmetics.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
April 2017 in “Journal of Investigative Dermatology” Targeted siRNA therapy may be a promising treatment for KID syndrome by reducing mutant gene expression and improving cell communication.
11 citations
,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
8 citations
,
September 2013 in “Molecular carcinogenesis” Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.
24 citations
,
May 2009 in “The FASEB Journal” Akt2 and SGK3 are both important for normal hair growth and development.
October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology” 54 citations
,
February 1994 in “Journal of Investigative Dermatology” 5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.